Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Phase I

Mindstate Design Labs

1 Drug Candidate

Mindstate Design Labs is a San Francisco-based biotech using AI (the Osmanthus platform, trained on 70,000+ psychedelic experience reports) to design precision psychedelic therapeutics. Their lead compound MSD-001 (5-MeO-MiPT) completed Phase 1 in July 2025, confirming safety and novel non-hallucinogenic psychoactive effects. The company is now advancing fixed-dose combinations for targeted therapeutic states.

Drug Pipeline

1

MSD-001

Phase I

5-MeO-MiPT oral formulation. Phase 1 completed July 2025 (CHDR, Netherlands, n=52). Non-hallucinogenic but psychoactive; dose-proportional PK. Advancing to fixed-dose combination trials for anxiety, insight, and aesthetic perception.

Quick Facts

Type
Private Biotech
Founded
2022
Lead Stage
Phase I
Website
Visit